Is your treatment what more than 1,100 Oncologists recommend?
The information provided below is meant to help you understand the role of your uterine biology in the cancer treatment decisions, as well as the role of other tools used in determining your ability to receive chemotherapy or targeted therapy (precision medicine).
In 2016, there are 60,050 new cases of endometrial (uterine) cancer diagnoses in the United States (CA Cancer J Clin 2016; 66(1):7-30), this cancer is increasing due to increased life expectancy (older age) and obesity. Uterine cancer is the most common gynecologic malignancy and 75% of women diagnosed with endometrial cancer are postmenopausal. The lifetime average risk for developing endometrial cancer is about 2.6% for a woman.
Uterine cancer begins in the uterine lining (endometrium) and is classified as either type I or type II.
Three different approaches to treating endometrial cancer are available.
This website is designed to outline in detail your chemotherapy and/or targeted therapy options and offer you personalized information about the best options to yield optimal survival and quality of life. Treatment plans are based on the surgical stage, grade and the histologic subtypes of the endometrial cancer. You find the information from the pathology report from your treating physician and input into the questionaires for your report.
Multiple factors affect your treatment options including:
Even though the standard of treatment is outlined, your individual tolerability to the optimal uterine treatment plan will depend on your overall health, i.e. whether you have other illness (diabetes, heart disease, liver disease, arthritis, or kidney disease). All uterine cancer treatment are recommended based on expertise’s opinions from multiple national guidelines (NCCN, ASCO, ESMO, ASTRO). Another assessment tool that your treating physicians may use to determine your ability to tolerate treatment is called ECOG performance status as described below:
ECOG PERFORMANCE STATUS
Grade 0: Fully active, able to carry on all activity
Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out light house work, office work
Grade 2: Ambulatory and capable of all self-care but unable to carry out any work activities
Grade 3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
Grade 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
(Am J Clin Oncol 1982: 5: 649-655)
Finally, chemotherapy and targeted therapies can result in unpleasant side effects such as hair loss, numbness of fingers or toes, cardiac toxicity, nausea, vomiting, diarrhea, abnormal liver function or low white blood cell count that could cause infection, and fatigue. However, advances in the oncology field have led to numerous supportive measures, such as white blood cell growth support (i.e. Neulasta) or anti-nausea medications (such as Zofran), that help to control most side effects when used as prescribed.
The best time to use this service (based on more than 1,100 cancer experts) is after you have learned the details of your cancer and treatment plan from your treating physicians, and would like to clarify and confirm that your treatment is the best option for your cancer. This questionnaire is used mainly for drug treatment in medical oncology.